Glenmark Pharmaceuticals share price
You have to be logged in to add this to Watchlist.- ₹2,320.70(-0.84%)May 15, 2026 15:29:00 PM IST
- NSE
- BSE
- Vol : 267.07 K (NSE + BSE)Last 20 day avg : 767.35 K
Glenmark Pharmaceuticals is trading -0.84% lower at Rs 2,320.70 as compared to its last closing price. Glenmark Pharmaceuticals has been trading in the price range of 2,366.90 & 2,317.90. Glenmark Pharmaceuticals has given 15.01% in this year & -1.31% in the last 5 days. Glenmark Pharmaceuticals has TTM P/E ratio 53.92 as compared to the sector P/E of 24.31.There are 9 analysts who have initiated coverage on Glenmark Pharmaceuticals. There are 5 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 403.21 Crores in its last quarter.Listed peers of Glenmark Pharmaceuticals include Dr Reddy's Laboratories (2.62%), Cipla (-0.49%), Divi's Laboratories (-2.41%).The Mutual Fund holding in Glenmark Pharmaceuticals was at 16.80% in 31 Mar 2026. The MF holding has decreased from the last quarter. The FII holding in Glenmark Pharmaceuticals was at 20.35% in 31 Mar 2026. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on May 17, 2026, 06:42 PM UTC
- BetaLow volatility0.60Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.28The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.21Annual dividends as a percentage of the stock price.
- PEG RatioIndicates overvaluation17.26The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
|
| ||||
|
| ||||
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Dr Reddy's Laboratories | Bullish | 1,336.95 | 2.62 | 1,11,584.24 | 18.63 | 3.14 | 0.63 | 2.34 |
| Cipla | Moderately Bullish | 1,431.55 | -0.49 | 1,16,013.10 | 22.95 | 3.87 | 0.87 | 0.81 |
| Divi's Laboratories | Bullish | 6,755.00 | -2.41 | 1,78,679.99 | 78.61 | 11.52 | 0.46 | 0.01 |
| Torrent Pharmaceuticals | Bullish | 4,386.00 | -0.52 | 1,48,148.92 | 67.32 | 17.1 | 0.83 | 17.62 |
| Sun Pharmaceutical Industries | Bullish | 1,879.90 | 0.90 | 4,51,076.67 | 36.24 | 5.77 | 0.92 | 0.50 |
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-01-30 | Quarterly Results |
| 2025-11-14 | Quarterly Results |
| 2025-09-26 | Interim Dividend |
| 2025-08-14 | Quarterly Results |
| 2025-05-23 | Audited Results & Final Dividend |
- IndustryBiotechnology & Drugs
- ISININE935A01035
- BSE Code532296
- NSE CodeGLENMARK
Glenmark Pharmaceuticals is trading at 2320.70 as on Fri May 15 2026 09:59:00. This is -0.84% lower as compared to its previous closing price of 2340.30.
The market capitalization of Glenmark Pharmaceuticals is 65490.35 Cr as on Fri May 15 2026 09:59:00.
The average broker rating on Glenmark Pharmaceuticals is Buy. The breakup of analyst rating is given below -
- 5 analysts have given a strong buy rating
- 2 analysts have given a buy rating
- 1 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 1 analysts have given a strong sell rating
The 52 wk high for Glenmark Pharmaceuticals is 2471.05 whereas the 52 wk low is 1360.00
Glenmark Pharmaceuticals can be analyzed on the following key metrics -
- TTM P/E: 53.92
- Sector P/E: 24.31
- Dividend Yield: 0.21%
- D/E ratio: -
Glenmark Pharmaceuticals reported a net profit of 1047.10 Cr in 2025.
The Mutual Fund Shareholding was 16.80% at the end of 31 Mar 2026.
EQUITY QUICK LINKS
Glenmark Pharmaceuticals QUICK LINKS
FROM MARKETS
RELATED LINKS
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.